![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » INVESTIGATORS PRESENT TARGRETIN DATA AT WORLD LUNG CANCER
INVESTIGATORS PRESENT TARGRETIN DATA AT WORLD LUNG CANCER
July 6, 2005
Results of Ligand Pharmaceuticals' two pivotal Phase III studies (SPIRIT I & SPIRIT II) of Targretin (bexarotene) capsules in front-line combination therapy with standard chemotherapy to treat advanced non-small cell lung cancer (NSCLC) were presented at the 11th World Conference on Lung Cancer in Barcelona, Spain.
Intent to treat analysis of both SPIRIT II (Targretin with carboplatin/paclitaxel vs. carboplatin/paclitaxel alone) and SPIRIT I (Targretin plus cisplatin/vinorelbine vs. cisplatin/vinorelbine alone) showed that addition of Targretin to either chemotherapeutic regimen did not improve overall survival nor progression free survival, as has been previously reported at ASCO on May 14.
Further subset analysis of both trials showed that a sizable group of patients developed high grade (NCI grade 3 or 4) hypertriglyceridemia early on during treatment (within 3 weeks) on the Targretin arm. Ongoing additional biochemical and genetic marker analysis is being conducted to optimize a biomarker approach that could help identify determinants of survival and provide the basis for patient selection in future confirmatory studies.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct